These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6709674)

  • 21. Potentiation of cocaine and d-amphetamine toxicity with caffeine.
    Derlet RW; Tseng JC; Albertson TE
    Am J Emerg Med; 1992 May; 10(3):211-6. PubMed ID: 1586430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potentiation of amphetamine-mediated responses in caffeine-sensitized rats involves modifications in A2A receptors and zif-268 mRNAs in striatal neurons.
    Tronci E; Simola N; Carta AR; De Luca MA; Morelli M
    J Neurochem; 2006 Aug; 98(4):1078-89. PubMed ID: 16771831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-injurious behavior produced in rats by daily caffeine and continuous amphetamine.
    Mueller K; Saboda S; Palmour R; Nyhan WL
    Pharmacol Biochem Behav; 1982 Oct; 17(4):613-7. PubMed ID: 6891061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute effects of caffeine in normal prepubertal boys.
    Elkins RN; Rapoport JL; Zahn TP; Buchsbaum MS; Weingartner H; Kopin IJ; Langer D; Johnson C
    Am J Psychiatry; 1981 Feb; 138(2):178-83. PubMed ID: 7457638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Caffeine cross-tolerance to selective dopamine D1 and D2 receptor agonists but not to their synergistic interaction.
    Garrett BE; Holtzman SG
    Eur J Pharmacol; 1994 Sep; 262(1-2):65-75. PubMed ID: 7813580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolerance to caffeine-induced stimulation of locomotor activity in rats.
    Finn IB; Holtzman SG
    J Pharmacol Exp Ther; 1986 Aug; 238(2):542-6. PubMed ID: 3735131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of NMDA receptor involvement in caffeine-induced locomotor stimulation and tolerance in rats.
    Powell KR; Holtzman SG
    Pharmacol Biochem Behav; 1998 Feb; 59(2):433-8. PubMed ID: 9476992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction between caffeine and methamphetamine by means of ambulatory activity in mice.
    Fujii W; Kuribara H; Tadokoro S
    Yakubutsu Seishin Kodo; 1989 Jun; 9(2):225-31. PubMed ID: 2816095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of amphetamine, caffeine and methylphenidate on the locomotor activity of rats in an unfamiliar environment.
    Marriott AS
    Int J Neuropharmacol; 1968 Nov; 7(6):487-91. PubMed ID: 5712878
    [No Abstract]   [Full Text] [Related]  

  • 30. Separate neural substrates of the locomotor-activating properties of amphetamine, heroin, caffeine and corticotropin releasing factor (CRF) in the rat.
    Swerdlow NR; Koob GF
    Pharmacol Biochem Behav; 1985 Aug; 23(2):303-7. PubMed ID: 3877311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microinjection of a glutamate antagonist into the nucleus accumbens reduces psychostimulant locomotion in rats.
    Pulvirenti L; Swerdlow NR; Koob GF
    Neurosci Lett; 1989 Aug; 103(2):213-8. PubMed ID: 2771183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Caffeine-phenylethylamine combinations mimic the amphetamine discriminative cue.
    Holloway FA; Michaelis RC; Huerta PL
    Life Sci; 1985 Feb; 36(8):723-30. PubMed ID: 3974408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of calcium channel entry blockers on cocaine and amphetamine-induced motor activities and toxicities.
    Ansah TA; Wade LH; Shockley DC
    Life Sci; 1993; 53(26):1947-56. PubMed ID: 8255157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Locomotor activity stimulation in rats produced by dopamine in the nucleus accumbens: potentiation by caffeine.
    Andén NE; Jackson DM
    J Pharm Pharmacol; 1975 Sep; 27(9):666-70. PubMed ID: 241810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitization and individual differences to IP amphetamine, cocaine, or caffeine following repeated intra-cranial amphetamine infusions.
    Hooks MS; Jones GH; Liem BJ; Justice JB
    Ann N Y Acad Sci; 1992 Jun; 654():444-7. PubMed ID: 1632599
    [No Abstract]   [Full Text] [Related]  

  • 36. Tolerance to oral and IP caffeine: locomotor activity and pharmacokinetics.
    Lau CE; Falk JL
    Pharmacol Biochem Behav; 1994 Jun; 48(2):337-44. PubMed ID: 8090799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-lasting tolerance to stimulatory effects of perinatal caffeine treatment.
    Lombardelli G; Balduini W; Feduzi A; Peruzzi G; Cattabeni F
    Psychopharmacology (Berl); 1984; 84(2):285-6. PubMed ID: 6438691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Caffeine potentiation of amphetamine: implications for hyperkinesis therapy.
    Schechter MD
    Pharmacol Biochem Behav; 1977 Mar; 6(3):359-61. PubMed ID: 558624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of nicotine, caffeine, and their combination on locomotor activity in rats.
    Cohen C; Welzl H; Bättig K
    Pharmacol Biochem Behav; 1991 Sep; 40(1):121-3. PubMed ID: 1780334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delta-opioid receptor antagonists attenuate motor activity induced by amphetamine but not cocaine.
    Jones DN; Bowen WD; Portoghese PS; Holtzman SG
    Eur J Pharmacol; 1993 Nov; 249(2):167-77. PubMed ID: 8287898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.